Author:
Yung L,Cunningham D,Hancock B,Smith P,Maclennan K,Linch D,McMillan A
Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. Cline MJ (1973) Adrenal steroids in the treatment of malignant hematologic disease. Med Clin N Am 57 (5): 1203–1209
2. Crawley CR, Foran JM, Gupta RK, Rohatiner AZ, Summers K, Matthews J, Micallef INM, Radford J, Johnson SA, Honhson PW, Sweetenham JW, Lister TA (2000) A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol 11 (7): 861–865
3. Greenstein S, Ghias K, Krett NL, Rosen ST (2002) Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 8 (6): 1681–1694
4. Marcus R, Hagenbeek A, Eghbali H, Monfardini E, Resegotti E, Hoskin J, de Wolf-Peeters C, Maclennan K, Staab-Renner E, Schott A, Teodorovic I, Negrouk A, Glabbeke M, Linch D (2002) Fludarabine versus CVP in newly diagnosed patients with stages III/IV low grade non-Hodgkin's lymphoma. Final analysis of prospective randomised phase III Intergroup study. Ann Oncol 13 (Suppl 2): 56
5. Mainwaring PN, Cunningham D, Gregory W, Hoskin P, Hancock B, Norton AJ, Maclennan K, Smith P, Vaughan Hudson G, Linch D (2001) Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 97 (10): 2991–2997
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献